Press Releases
Meridian BioGroup acquired by Pace® Life Sciences
Expanding Regulatory, Compliance, and Validation Capabilities to the Biotechnology and Pharmaceutical Markets
By
Meridian BioGroup
|
We are excited to announce, that Meridian BioGroup has been acquired by Pace® Life Sciences. The acquisition allows Pace® to provide regulatory and quality consulting services to support clients throughout the drug development process and improve commercial compliance in FDA-regulated environments. President of Pace® Life Sciences Greg Kupp said, “The addition of the Meridian BioGroup team … Read more
A single injection hepatitis B cure attracts international attention
Dr. Yong-Yuan Zhang presents in Paris, Seoul, and Washington DC in 2022
By
April Bartel
|
Frederick, MD – HBVtech, a biopharma startup company within the Frederick Innovation Technology Center (FITCI), is garnering international attention for its work creating a single-dose injection-based hepatitis B cure. Founder and Chief Science Officer, Dr. Yong-Yuan Zhang is well known for his research and writing on the topic of hepatitis, including related functional genomics and … Read more
AFFORDABLE POINT OF SERVICE HEALTHCARE ACCESS COMES TO MARYLANDERS
MARYLAND BUSINESSES PARTNERSHIP TO PROVIDE TELEHEALTH PLATFORM TO MITIGATE HEALTH INEQUITY
By
Ashok Kapur, Hawkeye MedTech
|
Columbia, MD, July 18, 2022 – Hawkeye Med Tech, Inc, a Maryland Medtech company has partnered with the Kiosk Group, Ltd,. to produce one-of-a-kind Portable TotalCare Telehealth StationTM or PTTS. PTTS is a Made in Maryland integrated telehealth tablet, blood pressure machine and pulse oximeter. PTTS not only enables users to get scheduled virtual medical and mental … Read more
Mesa Science Associates Receives Grant to Study Marfan Syndrome Treatment
Development of Cobinamide as a Novel Treatment for Aortic Aneurysms of Marfan Syndrome: Phase I Pharmacokinetic Studies
By
Mesa Associates, Inc.
|
Mesa Science Associates Inc. (MSA) received a Phase I Small Business Innovative Research Grant (SBIR) from the National Institutes of Health (NIH) entitled “Development of Cobinamide as a Novel Treatment for Aortic Aneurysms of Marfan Syndrome: Phase I Pharmacokinetic Studies.”Upon receiving this notification, Mr. Michael Mesa, President of MSA, “stated that this grant results from … Read more
FITCI Grad BioFactura Announces Activation of a $15.9M Contract Option
Smallpox Biodefense Therapeutic, contract valued at up to $68.2 million
By
Darryl Sampey, Ph.D., CEO
|
FREDERICK, MARYLAND, JULY 14, 2022: BioFactura today announced its second contract option activation of $15.9 million from the Biomedical Advanced Research and Development Authority (BARDA) to advance development of an antibody cocktail therapeutic for the treatment of smallpox. This funding is part of BioFactura’s prime contract valued at up to $68.2 million for the advanced … Read more
TEDCO Invests in FITCI Member, Alirtify, a Rural Maryland Pre-Seed Company
Alirtify is an intelligence-gathering platform
By
Tammi Thomas, Chief Marketing & Communications Officer, TEDCO tthomas@tedco.md
|
July 5, 2022—TEDCO, Maryland’s economic engine for technology companies (and a FITCI founding partner), announced today that its Rural Business Innovation Initiative (RBII) made a $25,000 investment in Alirtify, an intelligence-gathering platform based in Frederick, Md. “This new funding from TEDCO will help Alirtify expand and move its platform to the next level,” said Chuck Ernst, RBII mentor, Western … Read more
THERADAPTIVE: shaping the future of regenerative medicine at military treatment facilities
Advanced theraputic can mean the difference between amputation and limb preservation
By
The Geneva Foundation
|
Theradaptive is shaping the future of regenerative medicine with a new platform to deliver therapeutics that promote targeted native tissue repair. Their lead therapeutic, AMP2, is applied to an orthopedic implant to regenerate damaged bone, therefore significantly helping to speed up the injury healing process. For service members with combat trauma this can mean the … Read more
Theradaptive Secures Third FDA Breakthrough Designation for Spinal Fusion
Theradaptive’s technology re-grows bone
By
Serena Lertora serena.lertora@theradaptive.com
|
FREDERICK, Md. and BOSTON, June 22, 2022 /PRNewswire/ — Theradaptive, a privately held biopharmaceutical company pioneering a new class of regenerative implants announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Medical Device designation for the use of OsteoAdapt SP in Anterior Lumbar Interbody Fusion. This is the third Breakthrough Designation for Theradaptive in spinal fusion, … Read more
Veralox Therapeutics Announces Favorable Results of Phase 1 Studies of VLX-1005
A novel small molecule 12-LOX inhibitor, awarded Fast Track designation by US Food and Drug Administration
By
|
for Treatment of Heparin-Induced Thrombocytopenia FREDERICK, Md., June 13, 2022 /PRNewswire/ — Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat serious immuno-inflammatory diseases with significant unmet medical needs, today announced favorable results from the Company’s Phase 1 clinical program for VLX-1005, a novel 12-LOX inhibitor being developed for the treatment and prevention of … Read more
KnowledgeNet.ai Achieves SOC 2 Type II Compliance
KnowledgeNet.ai meets the highest information security standards following an independent audit
By
James Alvord
|
FREDERICK MD, June 7, 2022 – KnowledgeNet.ai, a leader in collaboration intelligence and knowledge sharing platform, announces the successful completion of the System and Organization Controls (SOC) 2 Type II Audit. Created by the American Institute of Certified Public Accountants (AICPA), SOC 2® is a reporting framework that sets the benchmarks for managing systems, process … Read more
